Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1963 1
1964 2
1965 1
1966 2
1967 1
1968 3
1969 1
1970 6
1971 7
1972 13
1973 12
1974 8
1975 27
1976 39
1977 34
1978 41
1979 38
1980 53
1981 47
1982 37
1983 38
1984 30
1985 42
1986 29
1987 40
1988 50
1989 45
1990 29
1991 51
1992 31
1993 55
1994 39
1995 42
1996 41
1997 50
1998 44
1999 55
2000 63
2001 59
2002 60
2003 63
2004 78
2005 75
2006 75
2007 98
2008 84
2009 99
2010 133
2011 228
2012 242
2013 302
2014 310
2015 377
2016 453
2017 507
2018 516
2019 606
2020 736
2021 779
2022 778
2023 772
2024 380

Text availability

Article attribute

Article type

Publication date

Search Results

7,863 results

Results by year

Filters applied: . Clear all
Page 1
Prehospital Tranexamic Acid for Severe Trauma.
PATCH-Trauma Investigators and the ANZICS Clinical Trials Group; Gruen RL, Mitra B, Bernard SA, McArthur CJ, Burns B, Gantner DC, Maegele M, Cameron PA, Dicker B, Forbes AB, Hurford S, Martin CA, Mazur SM, Medcalf RL, Murray LJ, Myles PS, Ng SJ, Pitt V, Rashford S, Reade MC, Swain AH, Trapani T, Young PJ. PATCH-Trauma Investigators and the ANZICS Clinical Trials Group, et al. N Engl J Med. 2023 Jul 13;389(2):127-136. doi: 10.1056/NEJMoa2215457. Epub 2023 Jun 14. N Engl J Med. 2023. PMID: 37314244 Clinical Trial.
At 28 days after injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the placebo group had died (risk ratio, 0.79; 95% CI, 0.63 to 0.99). By 6 months, 123 of 648 patients (19.0%) in the tranexamic acid group and 1 …
At 28 days after injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the placebo group …
Tranexamic acid: a clinical review.
Ng W, Jerath A, Wąsowicz M. Ng W, et al. Anaesthesiol Intensive Ther. 2015;47(4):339-50. doi: 10.5603/AIT.a2015.0011. Epub 2015 Mar 23. Anaesthesiol Intensive Ther. 2015. PMID: 25797505 Free article. Review.
The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolytic, was first patented in 1957 and its use has been increasing in contrast to aprotinin, a serine protease inhibitor antifibrinolytic. ...
The evidence of their efficacy has been mounting for years. Tranexamic acid (TXA), a synthetic lysine-analogue antifibrinolyti …
Clinical use of tranexamic acid: evidences and controversies.
Colomina MJ, Contreras L, Guilabert P, Koo M, M Ndez E, Sabate A. Colomina MJ, et al. Braz J Anesthesiol. 2022 Nov-Dec;72(6):795-812. doi: 10.1016/j.bjane.2021.08.022. Epub 2021 Oct 7. Braz J Anesthesiol. 2022. PMID: 34626756 Free PMC article. Review.
Tranexamic acid (TXA) significantly reduces blood loss in a wide range of surgical procedures and improves survival rates in obstetric and trauma patients with severe bleeding. ...Severe events are rare in clinical trials, and literature reviews have shown tranex …
Tranexamic acid (TXA) significantly reduces blood loss in a wide range of surgical procedures and improves survival rates in o …
Tranexamic acid: Beyond antifibrinolysis.
Prudovsky I, Kacer D, Zucco VV, Palmeri M, Falank C, Kramer R, Carter D, Rappold J. Prudovsky I, et al. Transfusion. 2022 Aug;62 Suppl 1:S301-S312. doi: 10.1111/trf.16976. Epub 2022 Jul 14. Transfusion. 2022. PMID: 35834488 Review.
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients. ...
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthop …
Tranexamic acid - A narrative review for the emergency medicine clinician.
Wang K, Santiago R. Wang K, et al. Am J Emerg Med. 2022 Jun;56:33-44. doi: 10.1016/j.ajem.2022.03.027. Epub 2022 Mar 22. Am J Emerg Med. 2022. PMID: 35364476 Review.
INTRODUCTION: Over the last decade, tranexamic acid (TXA) has been incorporated into treatment algorithms for a multitude of emergent conditions and the evidence surrounding its role in emergency medicine continues to evolve. ...The role of TXA in other clinical sce …
INTRODUCTION: Over the last decade, tranexamic acid (TXA) has been incorporated into treatment algorithms for a multitude of e …
Tranexamic acid in pediatric hemorrhagic trauma.
Borgman MA, Nishijima DK. Borgman MA, et al. J Trauma Acute Care Surg. 2023 Jan 1;94(1S Suppl 1):S36-S40. doi: 10.1097/TA.0000000000003775. Epub 2022 Aug 31. J Trauma Acute Care Surg. 2023. PMID: 36044459 Clinical Trial.
There is strong evidence in adult literature that tranexamic acid (TXA) given within 3 hours from injury is associated with improved outcomes. ...
There is strong evidence in adult literature that tranexamic acid (TXA) given within 3 hours from injury is associated with im …
Tranexamic acid for childbirth: why, when, and for whom.
Sentilhes L, Madar H, Mattuizzi A, Froeliger A, Merlot B, Elleboode B, Deneux-Tharaux C. Sentilhes L, et al. Expert Rev Hematol. 2019 Sep;12(9):753-761. doi: 10.1080/17474086.2019.1642744. Epub 2019 Aug 5. Expert Rev Hematol. 2019. PMID: 31295414 Review.
Introduction: Postpartum hemorrhage (PPH) is a major cause of maternal death and severe maternal morbidity after childbirth. Areas covered: Tranexamic acid, an antifibrinolytic agent, reduces bleeding-related mortality in women with PPH, especially when administered …
Introduction: Postpartum hemorrhage (PPH) is a major cause of maternal death and severe maternal morbidity after childbirth. Areas covered: …
Tranexamic acid as a stopgap for low platelets?
Zwicker JI. Zwicker JI. Blood. 2022 Sep 15;140(11):1185-1186. doi: 10.1182/blood.2022017207. Blood. 2022. PMID: 36107459 Free article. No abstract available.
Tranexamic acid for safer surgery: the time is now.
UK Royal Colleges Tranexamic Acid in Surgery Implementation Group; Grocott MPW, Murphy M, Roberts I, Sayers R, Toh CH. UK Royal Colleges Tranexamic Acid in Surgery Implementation Group, et al. Br J Anaesth. 2022 Oct;129(4):459-461. doi: 10.1016/j.bja.2022.06.024. Epub 2022 Sep 5. Br J Anaesth. 2022. PMID: 36070986
Tranexamic acid reduces surgical bleeding. Consistent with previous research, the POISE-3 (Peri-Operative Ischemic Evaluation-3) trial found that tranexamic acid reduces major bleeding by 25% and with a low probability of any increase in thromboembolic …
Tranexamic acid reduces surgical bleeding. Consistent with previous research, the POISE-3 (Peri-Operative Ischemic Evaluation- …
Topical Tranexamic Acid Is Effective in Cementless Total Knee Arthroplasty.
Chambers S, Tidwell L, Kerkhof A, Smith R, Mihalko WM. Chambers S, et al. Orthop Clin North Am. 2020 Jan;51(1):7-11. doi: 10.1016/j.ocl.2019.08.002. Epub 2019 Oct 17. Orthop Clin North Am. 2020. PMID: 31739881 Review.
Surgical techniques used to decrease the amount of blood lost during the procedure range from tourniquets to electrocautery and, more recently, the use of antifibrinolytics. Currently, tranexamic acid is the most commonly used antifibrinolytic in arthroplasty proced …
Surgical techniques used to decrease the amount of blood lost during the procedure range from tourniquets to electrocautery and, more recent …
7,863 results

Searches related to "tranexamic acid"